Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $89.23 USD
Change Today -0.84 / -0.93%
Volume 5.6M
ESRX On Other Exchanges
Symbol
Exchange
ESRX is not on other exchanges.
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

express scripts holding co (ESRX) Snapshot

Open
$90.06
Previous Close
$90.07
Day High
$90.86
Day Low
$88.32
52 Week High
07/22/15 - $94.61
52 Week Low
10/16/14 - $68.78
Market Cap
60.3B
Average Volume 10 Days
4.1M
EPS TTM
$3.54
Shares Outstanding
675.7M
EX-Date
--
P/E TM
25.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for EXPRESS SCRIPTS HOLDING CO (ESRX)

express scripts holding co (ESRX) Details

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. The company’s PBM segment’s services include clinical solutions to enhance health outcomes, such as adherence, case coordination, and personalized medicine; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services for pharmaceutical manufacturers to collect scientific evidence to guide the use of medicines, as well as case management approach to manage care by integrating pre-certification, case management, and discharge planning services for patients. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists, and others. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

29,500 Employees
Last Reported Date: 02/23/15
Founded in 1986

express scripts holding co (ESRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.2M
President and Director
Total Annual Compensation: $1.3M
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $535.4K
Vice President
Total Annual Compensation: $332.0K
Compensation as of Fiscal Year 2014.

express scripts holding co (ESRX) Key Developments

Express Scripts Holding Mulls Acquisitions

Express Scripts Holding Company (NasdaqGS:ESRX) is seeking acquisitions. George Paz, Chairman and Chief Executive Officer of Express Scripts Holding, said, “So whether it be through share repurchases or through accretive acquisitions, our focus is to manage your capital, in a diligent manner to maximize return.”

Express Scripts Holding Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year Ending December 31, 2015; Provides Earnings Guidance for the Third Quarter of 2015

Express Scripts Holding Company reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $25,454.2 million against $25,111.0 million for the same period last year. Operating income was $1,132.7 million against $966 million for the same period last year. Income before income taxes was $1,006.4 million against $841.6 million for the same period last year. Net income attributable to the company was $600.1 million or $0.88 per diluted share against $515.2 million or $0.67 per diluted share for the same period last year. EBITDA attributable to the company, as reported was $1,714.9 million against $1,516.6 million a year ago. Adjusted EBITDA, attributable to the company was $1,794.5 million against $1,735.2 million a year ago. Adjusted EBITDA attributable to company per adjusted claim was $5.59 compared to $5.35 a year ago. Adjusted net income attributable to the company was $979.1 million or $1.44 per diluted share against $939.4 million or $1.23 per diluted share for the same period last year. For the six months, the company reported revenues of $50,353.8 million against $48,796.0 million for the same period last year. Operating income was $1,959.3 million against $1,675.2 million for the same period last year. Income before income taxes was $1,721.9 million against $1,437.4 million for the same period last year. Net income attributable to the company was $1,041.2 million or $1.47 per diluted share against $843.5 million or $1.09 per diluted share for the same period last year. Net cash provided by operating activities was $1,181.3 million against $1,189.5 million for the same period last year. Purchases of property and equipment were $107.1 million against $208.8 million for the same period last year. EBITDA attributable to the company, as reported was $3,092.2 million against $2,772.7 million a year ago. Adjusted EBITDA, attributable to the company was $3,306.6 million against $3,206.2 million a year ago. Adjusted EBITDA attributable to company per adjusted claim was $5.26 compared to $4.97 a year ago. Adjusted net income attributable to the company was $1,790.2 million or $2.53 per diluted share against $1,718.6 million or $2.12 per diluted share for the same period last year. For the year ending December 31, 2015, the company provided adjusted earnings per share attributable to the company in the range of $5.46 to $5.54 compared to previous guidance in the range of $5.37 to $5.47. Adjusted EBITDA is expected to be in the range of $6,960 million to $7,120 million compared to previous guidance of $6,925 million to $7,125 million. Adjusted EBITDA per adjusted claim is expected to be in the range of $5.30 to $5.50 compared to previous guidance of $5.25 to $5.45. Cash flow from operations is expected to be in the range of $4,500 million to $5,000 million compared to previous guidance of $4,500 million to $5,000 million. Effective income tax rate is expected to be in range of 37.5% to 37.7% compared to previous guidance in the range of 37.3% to 37.7%. Capital expenditure is expected in the range of $300 million to $350 million compared to previous guidance in the range of $300 million to $400 million. For the third quarter of 2015, the company expects adjusted claims in range of $320 million to $340 million and adjusted earnings per diluted share in range of $1.41 to $1.45.

Keith J. Ebling to Leave Express Scripts Holding Company as Executive Vice President and General Counsel

On July 24, 2015, Express Scripts Holding Company announced that Keith J. Ebling will be leaving the company to pursue other interests and no longer serves in the role of Executive Vice President and General Counsel, but remains employed with the company for an indeterminate period of time in order to facilitate a smooth and orderly transition.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESRX:US $89.23 USD -0.84

ESRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aetna Inc $113.79 USD +0.82
Anthem Inc $152.78 USD -1.49
Cardinal Health Inc $85.82 USD +0.84
Kroger Co/The $39.40 USD +0.16
Walgreens Boots Alliance Inc $95.91 USD -0.72
View Industry Companies
 

Industry Analysis

ESRX

Industry Average

Valuation ESRX Industry Range
Price/Earnings 29.6x
Price/Sales 0.6x
Price/Book 3.8x
Price/Cash Flow 27.6x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXPRESS SCRIPTS HOLDING CO, please visit www.express-scripts.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.